CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance

Lumibao,Jan C.; Haak,Payton L.; Kolossov,Vladimir L.; Chen,Jee-Wei Emily; Stutchman,Jeremy; Ruiz,Alejandra; Sivaguru,Mayandi; Sarkaria,Jann N.; Harley,Brendan A.C.; Steelman,Andrew J.; Gaskins,H. Rex

doi:10.3892/ijo.2023.5565

CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance

Authors:
- Jan C. Lumibao
- Payton L. Haak
- Vladimir L. Kolossov
- Jee-Wei Emily Chen
- Jeremy Stutchman
- Alejandra Ruiz
- Mayandi Sivaguru
- Jann N. Sarkaria
- Brendan A.C. Harley
- Andrew J. Steelman
- H. Rex Gaskins
View Affiliations

Affiliations: Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA, Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905,USA
Published online on: August 25, 2023 https://doi.org/10.3892/ijo.2023.5565
Article Number: 117
Copyright: © Lumibao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (EGFRvIII). The amplification of the CHCHD2 gene was found to be associated with a decreased patient overall and progression‑free survival. The CHCHD2 mRNA levels were increased in high‑vs. low‑grade glioma, IDH‑wt GBMs, and in tumor vs. non‑tumor tissue. Additionally, CHCHD2 protein expression was greatest in invasive, EGFRvIII‑expressing patient‑derived samples. The CRISPR‑Cas9‑mediated knockout of CHCHD2 in EGFRvIII‑expressing U87 cells resulted in an altered mitochondrial respiration and glutathione status, in decreased cell growth and invasion under both normoxic and hypoxic conditions, and in an enhanced sensitivity to cytotoxic agents. CHCHD2 was distributed in both the mitochondria and nuclei of U87 and U87vIII cells, and the U87vIII cells exhibited a greater nuclear expression of CHCHD2 compared to isogenic U87 cells. Incubation under hypoxic conditions, serum starvation and the reductive unfolding of CHCHD2 induced the nuclear accumulation of CHCHD2 in both cell lines. Collectively, the findings of the present study indicate that CHCHD2 mediates a variety of GBM characteristics, and highlights mitonuclear retrograde signaling as a pathway of interest in GBM cell biology.

View Figures

View References

1	Barnholtz-Sloan JS, Ostrom QT and Cote D: Epidemiology of brain tumors. Neurol Clin. 36:395–419. 2018. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
3	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 164:550–563. 2016. View Article : Google Scholar : PubMed/NCBI
5	Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 18:1373–1385. 2017. View Article : Google Scholar
6	Gan HK, Kaye AH and Luwor RB: The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754. 2009. View Article : Google Scholar : PubMed/NCBI
7	Parker JJ, Canoll P, Niswander L, Kleinschmidt-DeMasters BK, Foshay K and Waziri A: Intratumoral heterogeneity of endogenous tumor cell invasive behavior in human glioblastoma. Sci Rep. 8:180022018. View Article : Google Scholar :
8	Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, et al: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 12:95–103. 2010. View Article : Google Scholar : PubMed/NCBI
9	Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, et al: A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 126:185–192. 2016. View Article : Google Scholar :
10	Wei Y, Vellanki R, Coyaud É, Ignatchenko V, Li L, Krieger J, Taylor P, Tong J, Pham NA, Liu G, et al: CHCHD2 is coamplified with EGFR in NSCLC and regulates mitochondrial function and cell migration. Mol Cancer Res. 13:1119–1129. 2015. View Article : Google Scholar : PubMed/NCBI
11	Cheng Q, Qu D, Lu Z and Zhang L: Knockdown of CHCHD2 inhibits migration and angiogenesis of human renal cell carcinoma: A potential molecular marker for treatment of RCC. Oncol Lett. 17:765–772. 2019.PubMed/NCBI
12	Aras S, Maroun MC, Song Y, Bandyopadhyay S, Stark A, Yang Z, Long MP, Grossman LI and Fernández-Madrid F: Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis. BMC Cancer. 19:4112019. View Article : Google Scholar : PubMed/NCBI
13	Modjtahedi N, Tokatlidis K, Dessen P and Kroemer G: Mitochondrial proteins containing Coiled-Coil-Helix-Coiled-Co il-Helix (CHCH) domains in health and disease. Trends Biochem Sci. 41:245–260. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhou ZD, Saw WT and Tan EK: Mitochondrial CHCHD-containing proteins: Physiologic functions and link with neurodegenerative diseases. Mol Neurobiol. 5:5547–5549. 2017. View Article : Google Scholar
15	Aras S, Bai M, Lee I, Springett R, Hüttemann M and Grossman LI: MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. Mitochondrion. 20:43–51. 2015. View Article : Google Scholar
16	Baughman JM, Nilsson R, Gohil VM, Arlow DH, Gauhar Z and Mootha VK: A computational screen for regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis. PLoS Genet. 5:e10005902009. View Article : Google Scholar :
17	Meng H, Yamashita C, Shuba-Fukushima K, Inoshita T, Funayama M, Sato S, Hatta T, Natsume T, Umitsu M, Takagi J, et al: Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat Commun. 8:155002017. View Article : Google Scholar : PubMed/NCBI
18	Seo M, Lee WH and Suk K: Identification of novel cell migration-promoting genes by a functional genetic screen. FASEB J. 24:464–478. 2010. View Article : Google Scholar
19	Liu Y, Clegg HV, Leslie PL, Di J, Tollini LA, He Y, Kim TH, Jin A, Graves LM, Zheng J and Zhang Y: CHCHD2 inhibits apoptosis by interacting with Bcl-x L to regulate Bax activation. Cell Death Differ. 22:1035–1046. 2015. View Article : Google Scholar :
20	Aras S, Pak O, Sommer N, Finley R Jr, Hüttemann M, Weissmann N and Grossman LI: Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2. Nucleic Acids Res. 41:2255–2266. 2013. View Article : Google Scholar
21	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar
22	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:p112013. View Article : Google Scholar
23	Bowman RL, Wang Q, Carro A, Verhaak RGW and Squatrito M: GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 19:139–141. 2017. View Article : Google Scholar
24	Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A and James CD: Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 12:2264–2271. 2006. View Article : Google Scholar : PubMed/NCBI
25	Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB and James CD: Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 6:1167–1674. 2007. View Article : Google Scholar : PubMed/NCBI
26	Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, et al: Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res. 26:1094–1104. 2020. View Article : Google Scholar
27	Hüttemann M, Lee I, Liu J and Grossman LI and Grossman LI: Transcription of mammalian cytochrome c oxidase subunit IV-2 is controlled by a novel conserved oxygen responsive element. FEBS J. 274:5737–5748. 2007. View Article : Google Scholar : PubMed/NCBI
28	Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F: Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 8:2281–2308. 2013. View Article : Google Scholar : PubMed/NCBI
29	Wong N, Liu W and Wang X: WU-CRISPR: Characteristics of functional guide RNAs for the CRISPR/Cas9 system. Genome Biol. 16:2182015. View Article : Google Scholar : PubMed/NCBI
30	Kolossov VL, Beaudoin JN, Ponnuraj N, DiLiberto S, Hanafin WP, Kenis PJA and Gaskins HR: Thiol-based antioxidants elicit mitochondrial oxidation via respiratory complex III. Am J Physiol Cell Physiol. 309:C81–C91. 2015. View Article : Google Scholar : PubMed/NCBI
31	Vichai V and Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 1:1112–1116. 2006. View Article : Google Scholar
32	Joshi AD, Botham RC, Schlein LJ, Roth HS, Mangraviti A, Borodovsky A, Tyler B, Joslyn S, Looper JS, Podell M, et al: Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget. 8:80124–80138. 2017. View Article : Google Scholar : PubMed/NCBI
33	Chen JE, Lumibao J, Blazek A, Gaskins HR and Harley B: Hypoxia activates enhanced invasive potential and endogenous hyaluronic acid production by glioblastoma cells. Biomater Sci. 6:854–862. 2018. View Article : Google Scholar : PubMed/NCBI
34	Chen JE, Pedrons S and Harley BAC: The combined influence of hydrogel stiffness and matrix-bound hyaluronic acid content on glioblastoma invasion. Macromol Biosci. 17: View Article : Google Scholar : 2017.
35	Chen JE, Pedron S, Shyu P, Hu Y, Sarkaria JN and Harley BAC: Influence of hyaluronic acid transitions in tumor microenvironment on glioblastoma malignancy and invasive hehavior. Front Mater. 5:392018. View Article : Google Scholar
36	Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: The somatic genomic landscape of glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
37	Divakaruni AS, Paradyse A, Ferrick DA, Murphy AN and Jastroch M: Analysis and interpretation of microplate-based oxygen consumption and pH data. Methods Enzymol. 547:309–354. 2014. View Article : Google Scholar
38	Hanschmann EM, Godoy JR, Berndt C, Hudemann C and Lillig CH: Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: From cofactors to antioxidants to redox signaling. Antioxid Redox Signal. 19:1539–1605. 2013. View Article : Google Scholar : PubMed/NCBI
39	Estrela JM, Ortega A and Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 43:143–181. 2006. View Article : Google Scholar : PubMed/NCBI
40	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
41	Chen L, Li X, Liu L, Yu B, Xue Y and Liu Y: Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. Oncol Rep. 33:1465–1474. 2015. View Article : Google Scholar : PubMed/NCBI
42	Huberfeld G and Vecht CJ: Seizures and gliomas-towards a single therapeutic approach. Nat Rev Neurol. 12:204–216. 2016. View Article : Google Scholar : PubMed/NCBI
43	Eisenberg-Bord M and Schuldiner M: Ground control to major TOM: Mitochondria-nucleus communication. FEBS J. 284:196–210. 2017. View Article : Google Scholar
44	Yogev O, Naamati A and Pines O: Fumarase: A paradigm of dual targeting and dual localized functions. FEBS J. 278:4230–4242. 2011. View Article : Google Scholar : PubMed/NCBI
45	Zhuang J, Wang PY, Huang X, Chen X, Kang JG and Hwang PM: Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity. Proc Natl Acad Sci USA. 110:17356–17361. 2013. View Article : Google Scholar : PubMed/NCBI
46	Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, Hashimoto K, Zhang N, Flaim E and Michelakis ED: A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell. 158:84–97. 2014. View Article : Google Scholar : PubMed/NCBI
47	Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, et al: Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab. 28:793–800.e2. 2018. View Article : Google Scholar :
48	Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XI, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, et al: Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15:827–237. 2012. View Article : Google Scholar : PubMed/NCBI
49	Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI
50	Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, et al: Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA. 108:16062–16067. 2011. View Article : Google Scholar : PubMed/NCBI
51	Zanotelli MR, Goldblatt ZE, Miller JP, Bordeleau F, Li J, VanderBurgh JA, Lampi MC, King MR and Reinhart-King CA: Regulation of ATP utilization during metastatic cell migration by collagen architecture. Mol Biol Cell. 29:1–9. 2018. View Article : Google Scholar :
52	Xie Q, Wu Q, Kim L, Miller TE, Liau BB, Mack SC, Yang K, Factor DC, Fang X, Huang Z, et al: RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. J Clin Invest. 126:2757–2772. 2016. View Article : Google Scholar :